FrancophonIA/ELRC3.0 huggingface dataset:
English: Up to two additional courses, each of 12 mg daily for 3 days, can be given at 12-month intervals.
Maltese: Jistgħu jingħataw sa żewġ korsijiet addizzjonali, bi 12 mg kull wieħed kuljum għal 3 ijiem, f'intervalli ta' 12-il xahar.
English: 1 See outcome of safety review carried out in 2019.
Maltese: 1 Ara r-riżultat tar-rieżami tas-siġurtà li sar fl-2019.
English: It must not be used in patients with uncontrolled hypertension (high blood pressure), patients who have had arterial dissection (tears) of the cervicocephalic arteries (blood vessels in the head and neck), stroke, angina pectoris (pains to the chest, jaw and back, brought on by physical effort and due to problems with the blood flow to the heart) or myocardial infarction (heart attack).
Maltese: Ma għandux jintuża f'pazjenti b'ipertensjoni mhux ikkontrollata (pressjoni tad-demm għolja), pazjenti li kellhom dissezzjoni arterjali (tiċrit) tal-arterji ċervikoċefaliċi (vażi tad-demm fir-ras u l-għonq), puplesija, anġina pectoris (uġigħ fis-sider, ix-xedaq u d-dahar, li jiġi permezz ta' sforz fiżiku u minħabba problemi bil-fluss taddemm lejn il-qalb) jew infart mijokardjali (attakk tal-qalb).
English: As for all medicines, data on the use of Lemtrada are continuously monitored.
Maltese: Bħal fil-każ tal-mediċini kollha, id-data dwar l-użu ta' Lemtrada hija ssorveljata kontinwament.
English: How is Lemtrada used?
Maltese: Kif jaħdem Lemtrada?
English: Lemtrada is given as an infusion (drip) into a vein over about 4 hours.
Maltese: Lemtrada jingħata bħala infużjoni (dripp) ġol-vina fuq perjodu ta' madwar 4 sigħat.
English: In MS, the immune system (the body's natural defences) malfunctions and attacks parts of the central nervous system (the brain, spinal cord and optic nerve [nerve that sends signals from the eye to the brain]), causing inflammation that damages the nerves and the insulation around them.
Maltese: Fl-MS, is-sistema immunitarja (id-difiżi naturali tal-ġisem) ma taħdimx tajjeb u tattakka partijiet missistema nervuża ċentrali (il-moħħ, l-ispina dorsali u n-nerv ottiku [nerv li jibgħat sinjali mill-għajn lejn il-moħħ]), u tikkawża infjammazzjoni li tagħmel ħsara lin-nervituri u lill-kisja ta' madwarhom.
English: The company will ensure that doctors expected to prescribe the medicine receive educational materials containing important safety information, and a checklist covering the necessary screening, medicines to reduce side effects, monitoring before, during and after infusion, and long-term monitoring of patients.
Maltese: Il-kumpanija se tiżgura li t-tobba li jkunu mistennija jippreskrivu l-mediċina jirċievu materjal edukattiv li jkun fih informazzjoni importanti dwar is-sigurtà, u lista ta' kontroll li tkopri l-iskrinjar meħtieġ, ilmediċini biex jitnaqqsu l-effetti sekondarji, il-monitoraġġ qabel, waqt u wara l-infużjoni, u l-monitoraġġ fit-tul tal-pazjenti.
English: Patients will receive a patient alert card and a guide explaining the risks with the medicine and symptoms of Lemtrada's serious side effects.
Maltese: Il-pazjenti se jirċievu kard ta' twissija tal-pazjent u gwida li tispjega r-riskji bilmediċina u s-sintomi tal-effetti sekondarji serji ta' Lemtrada.
English: With regards to safety, Lemtrada has rare but serious side effects, including disorders of the heart, blood vessels and immune system and measures have been put in place to minimise this risk.1
Maltese: Fir-rigward tas-sigurtà, Lemtrada għandu effetti sekondarji rari iżda serji, inklużi disturbi tal-qalb, vażi tad-demm u s-sistema immunitarja u miżuri ġew stabbiliti biex inaqqsu dan ir-riskju.
English: The most common side effects with Lemtrada (which may affect more than 1 in 5 people) are rash, headache, fever and respiratory tract infections (throat and chest infections).
Maltese: Leffetti sekondarji l-aktar komuni b'Lemtrada (li jistgħu jaffettwaw aktar minn persuna 1 minn kull 5) huma raxx, uġigħ ta' ras, deni u infezzjonijiet fis-sistema respiratorja (infezzjonijiet fil-griżmejn u ssider).
English: Lemtrada (alemtuzumab)
Maltese: Lemtrada jintuża għal pazjenti b':
English: For the full list of side effects of Lemtrada, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji ta' Lemtrada, ara l-fuljett ta' tagħrif.
English: What benefits of Lemtrada have been shown in studies?
Maltese: X'inhuma l-benefiċċji ta' Lemtrada li ħarġu mill-istudji?
English: When alemtuzumab attaches to the lymphocytes, it causes them to die, and they are replaced by new lymphocytes.
Maltese: Meta l-alemtużumab teħel mal-limfoċiti, din toqtolhom, u jiġu sostitwiti b'limfoċiti ġodda.
English: Lemtrada must not be used in patients with coagulopathy (problems with blood clotting) or in patients who are taking anti-platelet or anti coagulant therapy.
Maltese: Lemtrada m'għandux jintuża f'pazjenti b'koagulapatija (problemi bil-koagulazzjoni tad-demm) jew f'pazjenti li jkunu qed jieħdu terapija kontra l-pjastrini jew kontra l-koagulanti.
English: The full EPAR for Lamivudine Teva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: It is available as tablets (100 mg).
Maltese: Jiġi f'pilloli (100 mg).
English: Lamivudine Teva is a ‘generic medicine'.
Maltese: Lamivudine Teva huwa ‘mediċina ġenerika'.
English: The active substance in Lamivudine Teva, lamivudine, is an antiviral agent belonging to the class of the nucleoside analogues.
Maltese: Is-sustanza attiva f'Lamivudine Teva, il-lamivudina, hija antivirali li tappartjeni għall-klassi ‘nucleoside analogues'.
English: EPAR summary for the public lamivudine
Maltese: Sommarju tal-EPAR għall-pubbliku lamivudina
English: Lamivudine Teva is a medicine that contains the active substance lamivudine.
Maltese: Lamivudine Teva huwa mediċina li fiha s-sustanza attiva lamivudina.
English: Lamivudine Teva is used to treat adult patients who have chronic (long term) hepatitis B (a disease of the liver due to an infection by the hepatitis B virus).
Maltese: Lamivudine Teva jintuża għall-kura ta' pazjenti adulti li jkollhom epatite B kronika (fit-tul) (marda talfwied dovuta għal infezzjoni bir-virus tal-epatite B).
English: This is a summary of the European public assessment report (EPAR) for Lamivudine Teva.
Maltese: Dan huwa sommarju tar-Rapport Pubbliku Ewropew ta' Valutazzjoni (EPAR) għal Lamivudine Teva.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Lamivudine Teva on 23 October 2009.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq għal Lamivudine Teva valida fl-Unjoni Ewropea kollha fit-23 ta' Ottubru 2009.
English: What is Lamivudine Teva?
Maltese: X'inhu Lamivudine Teva?
English: Because Lamivudine Teva is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Zeffix.
Maltese: Billi Lamivudine Teva huwa mediċina ġenerika, l-istudji ġew limitati għal testitjiet biex jiddeterminaw ilbijoekwivalenza tiegħu mal-mediċina ta' referenza, Zeffix.
English: The CHMP concluded that, in accordance with EU requirements, Lamivudine Teva has been shown to have comparable quality and to be bioequivalent to Zeffix.
Maltese: Is-CHMP kkonkluda li, b'mod konformi mar-rekwiżiti tal-UE, intwera li Lamivudine Teva għandu kwalità komparabbli u li huwa bijoekwivalenti għal Zeffix.
English: What are the benefits and risks of Lamivudine Teva?
Maltese: X'inhu l-benefiċċju u r-riskju ta' Lamivudine Teva?
English: This means that Lamivudine Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Zeffix.
Maltese: Dan ifisser li Lamivudine Teva huwa simili għal ‘mediċina ta' referenza' diġà awtorizzata fl-Unjoni Ewropea (UE) bl-isem Zeffix.
English: Patients infected with a virus that has the ‘YMDD mutation' (a change in the virus's DNA that is often found after treatment with lamivudine) should take Lamivudine Teva in combination with another medicine against hepatitis B. For more information, please see the Summary of Product Characteristics (also part of the EPAR).
Maltese: Il-pazjenti infettati b'vajrus li għandu l-‘mutazzjoni YMDD' (‘YMDD mutation') (bidla fid-DNA ta' virus li spiss tinstab wara kura billamivudina) għandhom jieħdu Lamivudine Teva flimkien ma' mediċina oħra kontra l-epatite B.
English: It is used in patients with compensated liver disease (when the liver is damaged but functions normally), who also show signs that the virus is still multiplying, and have signs of liver damage (raised levels of the liver enzyme ‘alanine aminotransferase' [ALT] and signs of damage when liver tissue is examined under a microscope).
Maltese: Jintuża f'pazjenti li jbatu b'mard tal-fwied ikkompensat (meta l-fwied ikollu ħsara iżda jibqa' jaħdem sew), li jkollhom ukoll sinjali li l-vajrus ikun għadu qed jimmultiplika, u li jkollhom sinjali ta' ħsara fil-fwied (żieda fil-livelli tal-enzimi tal-fwied 'alanina aminotransferażi' [ALT] u sinjali ta' ħsara meta t-tessut tal-fwied jiġi analizzat taħt ilmikroskopju).
English: Why has Lamivudine Teva been approved?
Maltese: Għaliex ġie approvat Lamivudine Teva?
English: Because Lamivudine Teva is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine.
Maltese: Billi Lamivudine Teva huwa mediċina ġenerika u huwa bijoekwivalenti għall-mediċina ta' referenza, ilbenefiċċji u r-riskji jitqiesu li kienu l-istess bħal dawk tal-mediċina ta' referenza.
English: Lamivudine interferes with the action of a viral enzyme, DNA polymerase, which is involved in the formation of viral DNA.
Maltese: Il-lamivudina tinterferixxi mal-azzjoni ta' enzima virali msejħa DNA polimerażi, li għandha x'taqsam mal-formazzjoni ta' DNA virali.
English: How has Lamivudine Teva been studied?
Maltese: Kif ġie studjat Lamivudine Teva?
English: Treatment with Lamivudine Teva should be initiated by a doctor who has experience in the management of chronic hepatitis B. The recommended dose of Lamivudine Teva is 100 mg once a day.
Maltese: Id-doża tal-bidu rakkomandata ta' Lamivudine Teva hi 100 mg darba kuljum.
English: Therefore, the CHMP's view was that, as for Zeffix, the benefit outweighs the identified risk.
Maltese: Għaldaqstant, il-fehma tas-CHMP kienet li, bħal filkaż ta' Zeffix, il-benefiċċji huma akbar mir-riskji identifikati.
English: How does Lamivudine Teva work?
Maltese: Għal xiex jintuża Lamivudine Teva?
English: It contains the active substance mifamurtide.
Maltese: Fih is-sustanza attiva mifamurtide.
English: The most common side effects with Mepact (seen in more than 1 patient in 10) are anaemia (low red blood cell counts), loss of appetite, headache, dizziness, tachycardia (rapid heartbeat), hypertension (high blood pressure), hypotension (low blood pressure), dyspnoea (difficulty breathing), tachypnoea (rapid breathing), cough, vomiting, diarrhoea, constipation, abdominal pain (stomach ache), nausea, hyperhidrosis (excessive sweating), myalgia (muscle pain), arthralgia (joint pain), back pain, pain in extremity (the arms and legs), fever, chills, fatigue (tiredness), hypothermia (low body temperature), general pain, malaise (feeling unwell), asthenia (weakness) and chest pain.
Maltese: L-iktar effetti sekondarji komuni b'Mepact (li dehru f'iktar minn pazjent 1 minn kull 10) huma anemija (numru baxx ta' ċelloli tad-demm ħomor),nuqqas ta' aptit, uġigħ ta' ras, sturdament, takikardja (taħbit tal-qalb mgħaġġel), ipertensjoni (pressjoni għolja tad-demm), ipotensjoni (pressjoni baxxa tad-demm), dispneja (qtugħ ta' nifs), takipneja (nifs mgħaġġel), sogħla, rimettar, dijarrea, stitikezza, uġigħ ta' żaqq (uġigħ tal-istonku), nawsja, iperidrożi (ħruġ eċċessiv ta' għaraq), mjalġija (uġigħ fil-muskoli), artralġija (uġigħ fil-ġogi), uġigħ fid-dahar, uġigħ fl-estremitajiet (id-dirgħajn u s-saqajn), deni, kesħa, għeja, ipotemja (temperatura baxxa tal-ġisem), uġigħ ġenerali, ħass ħażin (ma tħossokx f'saħħtek), astenja (debbulizza) u uġigħ fis-sider.
English: Mepact mifamurtide
Maltese: Mifamurtide
English: The active substance in Mepact, mifamurtide, is an immunomodulator.
Maltese: Is-sustanza attiva f'Mepact, mifamurtide, hija immunomodulatur.
English: The patients were followed up for up to 10 years.
Maltese: Il-pazjenti ġew segwiti sa 10 snin wara.
English: Other information about Mepact:
Maltese: Informazzjoni oħra dwar Mepact:
English: This document is a summary of the European public assessment report (EPAR) for Mepact.
Maltese: Dan id-dokument huwa sommarju tar-Rapport ta' Valutazzjoni Pubblika Ewropew (EPAR) għal Mepact.
English: Mepact, used with other anticancer medicines, increased how long patients survived without their disease coming back: 68% of the patients receiving Mepact (231 out of 338) survived without the disease coming back, compared with 61% of the patients who did not receive it (207 out of 340).
Maltese: Mepact, meta użat ma' mediċini oħra ta' kontra l-kanċer, żied it-tul ta' żmien li fih il-pazjenti għexu mingħajr ma reġgħet feġġetilhom il-marda: 68% tal-pazjenti li kienu qed jirċievu Mepact (231 minn 338) għexu mingħajr ma reġgħet feġġet il-marda, meta mqabbla mal-61% tal-pazjenti li ma rċevewx din il-mediċina (207 minn 340).
English: The risk of dying was also reduced by 28% in patients receiving Mepact.
Maltese: Ir-riskju ta' mewt tnaqqas ukoll bi 28% f'pazjenti li kienu qed jirċievu Mepact.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Mepact is available here.
Maltese: Is-sommarju tal-opinjoni tal-Kumitat għal Prodotti Mediċinali Orfni għal Mepact huwa disponibbli hawnhekk.
English: Mepact has been studied in one main study involving 678 patients aged between one and 31 years with high-grade non-metastatic osteosarcoma.
Maltese: Mepact ġie studjat fi studju wieħed ewlieni li involva 678 pazjent b'osteosarkoma-mhux-metastatika ta' grad-għoli tal-etajiet bejn sena u 31 sena.
English: Because the number of patients with osteosarcoma is low, the disease is considered ‘rare', and Mepact was designated an ‘orphan medicine' (a medicine used in rare diseases) on 21 June 2004.
Maltese: Minħabba li l-għadd ta' pazjenti b'osteosarkoma huwa wieħed baxx, il-marda hija meqjusa bħala ‘rari', u Mepact ġie denominat bħala ‘mediċina orfni' (mediċina użata fil-mard rari) fil-21 ta' Ġunju 2004.
English: Mepact is a powder that is made up into a suspension for infusion (drip into a vein).
Maltese: Mepact huwa trab magħmul f'sospensjoni għall-infużjoni (dripp fil-vina).
English: What is Mepact?
Maltese: X'inhu Mepact?
English: For the full list of all side effects reported with Mepact, see the package leaflet.
Maltese: Għal-lista sħiħa ta' effetti sekondarji rrappurtati b'Mepact, ara lfuljett ta' tagħrif.
English: It must not be used at the same time as ciclosporin or other calcineurin inhibitors (medicines that reduce the activity of the immune system), or high doses of non-steroidal anti-inflammatory drugs (NSAIDs; used to treat pain and inflammation).
Maltese: M'għandux jintuża fl-istess ħin ma' ciclosporin jew inibituri oħrajn tal- calcineurin (mediċini li jnaqqsu l-attività tas-sistema immunitarja), jew dożi għoljin ta' mediċini anti-infjammatorji mhux sterojdali (NSAIDs; użati biex jikkuraw l-uġigħ u l-infjammazzjoni).
English: It works by activating macrophages and monocytes (types of white blood cell that form part of the immune system).
Maltese: Din taħdem billi tattiva makrofaġi u monoċiti (tipi ta' ċelloli tad-demm bojod li jiffurmaw parti mis-sistema immunitarja).
English: Why has Mepact been approved?
Maltese: Għaliex ġie approvat Mepact?
English: Mepact treatment should be started and supervised by a specialised doctor who has experience in diagnosing and treating osteosarcoma.
Maltese: It-trattament b'Mepact għandu jinbeda u jiġi ssorveljat minn tabib speċjalizzat li għandu esperjenza fid-dijanjożi u l-kura tal-osteosarkoma.
English: How has Mepact been studied?
Maltese: Kif ġie studjat Mepact?
English: What is the risk associated with Mepact?
Maltese: X'inhu r-riskju assoċjat ma' Mepact?
English: What benefit has Mepact shown during the studies?
Maltese: Liema benefiċċju wera Mepact waqt l-istudji mwettqa?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Mepact on 6 March 2009.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fuq is-suq madwar l-Unjoni Ewropea, għal Mepact fis-6 ta' Marzu 2009.
English: Mepact is used with other anticancer medicines after the cancer has been removed by surgery.
Maltese: Wara l-kirurġija biex jitneħħa l-kanċer, il-pazjenti kollha ngħataw taħlitiet differenti ta' mediċini ta' kontra l-kanċer.
English: 74.2 mg Implant
Maltese: 74.2 mg
English: 4 implants + 1 applicator
Maltese: 4 impjanti + applikatur
English: Subcutaneous use sachet (PET/LDPE/alu)
Maltese: Użu għal taħt il-ġilda Qartas (PET/LDPE/Alu)
English: Tresiba insulin degludec
Maltese: Tresiba insulina degludec
English: The full EPAR for Tresiba can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: After 26 weeks of treatment with Tresiba, the average reduction in HbA1c was 0.2 percentage points (HbA1c decreased from 8.2% to 8.0%) compared with a reduction of 0.3 percentage points with insulin detemir (HbA1c decreased from 8.0% to 7.7%).
Maltese: Wara 26 ġimgħa ta' kura bi Tresiba, it-tnaqqis medju fl-HbA1c kien ta' 0.2 punti perċentwali (HbA1c naqas minn 8.2% sa 8.0%) meta mqabbel ma' tnaqqis ta' 0.3 punti perċentwali bl-insulina detemir (HbA1c naqas minn 8.0% sa 7.7%).
English: Tresiba is a medicine that contains the active substance insulin degludec.
Maltese: Tresiba huwa mediċina li fiha s-sustanza attiva l-insulina degludec.
English: Other information about Tresiba
Maltese: Informazzjoni oħra dwar Tresiba
English: It is available as a solution for injection in a cartridge (100 units/ml) and in a pre-filled pen (100 units/ml and 200 units/ml).
Maltese: Tiġi bħala soluzzjoni għal injezzjoni fi skartoċċ (100 unità/ml) u f'pinna mimlija għal-lest (100 unità/ml u 200 unità/ml).
English: This is a summary of the European public assessment report (EPAR) for Tresiba.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Tresiba.
English: Tresiba has been studied in three main studies involving 1,578 adults with type 1 diabetes, where Tresiba (in combination with rapid acting mealtime insulin) was compared with insulin glargine or insulin detemir (other long acting insulins).
Maltese: Tresiba ġie studjat fi tliet studji ewlenin li involvew 1,578 pazjent bid-dijabete tat-tip 1, fejn Tresiba (f'kombinazzjoni ma' insulina li taġixxi malajr waqt il-ħin tal-ikel) tqabbel mal-insulina glargine jew linsulina detemir (insulina oħra li taġixxi fit-tul).
English: Across the studies, the average reduction in HbA1c levels with Tresiba treatment was 0.6 percentage points in adults with type 1 diabetes and 1.2 points in adults with type 2 diabetes.
Maltese: Fost l-istudji, it-tnaqqis medju fil-livelli ta' HbA1c b'kura bi Tresiba kien ta' 0.6 punti perċentwali f'adulti bid-dijabete tat-tip 1 u ta' 1.2 punti f'adulti bid-dijabete tat-tip 2.
English: Another main study involving 177 adults with type 2 diabetes investigated the effectiveness of combining Tresiba and liraglutide (a GLP-1 receptor agonist).
Maltese: Studju ieħor li involva 177 pazjent bid-dijabete tat-tip 2 investiga l-effikaċja tat-taħlita ta' Tresiba u liraglutide (agonisti tar-riċettur GLP-1).
English: Six other main studies involving 4,076 adults with type 2 diabetes compared Tresiba with insulin glargine, insulin detemir or sitagliptin (a medicine taken by mouth for type 2 diabetes).
Maltese: Sitt studji ewlenin oħra li involvew 4,076 pazjent bid-dijabete tat-tip 2 qabblu Tresiba mal-insulina glargine, l-insulina detemir jew sitagliptin (mediċina li tittieħed mill-ħalq għad-dijabete tat-tip 2).
English: What is Tresiba?
Maltese: X'inhu Tresiba?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Tresiba on 21 January 2013.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Tresiba fil-21 ta' Jannar 2013.
English: Why has Tresiba been approved?
Maltese: Għaliex ġie approvat Tresiba?
English: In addition Tresiba was compared with insulin detemir in one main study involving 350 children aged 1 to 18 years of age with type 1 diabetes.
Maltese: Barra minn hekk Tresiba tqabbel mal-insulina detemir fi studju ewlieni ieħor li involva 350 tifel u tifla li kellhom bejn 1 (sena) u 18-il sena bid-dijabete tat-tip 1.
English: Tresiba is used to treat type 1 and type 2 diabetes in adults and children aged 1 to 18 years of age.
Maltese: Tresiba jintuża fil-kura tad-dijabete ta' tip 1 u tip 2 fl-adulti u fit-tfal ta' bejn 1 (sena) u 18-il sena.
English: Tresiba is injected once a day, preferably at the same time every day.
Maltese: Tresiba jiġi injettat darba kuljum, preferibbilment fl-istess ħin kuljum.
English: The CHMP concluded that Tresiba is effective in controlling blood glucose levels in patients with type 1 and type 2 diabetes.
Maltese: Is-CHMP ikkonkluda li Tresiba huwa effettiv fil-kontroll tal-livelli ta' glukożju fid-demm f'pazjenti biddijabete tat-tip 1 u tat-tip 2.
English: In type 2 diabetes, Tresiba can be used alone or in combination with diabetes medicines given by mouth, GLP-1 receptor agonist medicines and rapid acting mealtime insulin.
Maltese: Fid-dijabete tat-tip 2, Tresiba jista' jintuża waħdu jew f'kombinazzjoni ma' mediċini orali tad-dijabete, mediċini agonisti tar-riċettur GLP-1 u ma' insulina li taġixxi malajr waqt il-ħin tal-ikel.
English: Tresiba is a replacement insulin that is very similar to the natural insulin with a difference that it is absorbed more slowly in the body and takes longer to reach its target.
Maltese: Tresiba huwa insulina ta' sostituzzjoni simili ħafna għall-insulina naturali bid-differenza li tiġi assorbita iktar bil-mod fil-ġisem u ddum iktar biex tilħaq l-għan tagħha.
English: All of the studies measured the level of a substance in the blood called glycosylated haemoglobin (HbA1c), which is the percentage of haemoglobin in the blood attached to glucose.
Maltese: L-istudji kollha kejlu l-livell ta' sustanza fid-demm imsejħa emoglobina glikosilata (HbA1c), li hija lperċentwal ta' emoglobina fid-demm imwaħħla mal-glukożju.
English: The company that markets Tresiba will provide educational materials to healthcare professionals expected to treat or dispense medicines to patients with diabetes, aimed particularly at raising awareness of the higher strength formulation of Tresiba in order to ensure that the patient is prescribed the correct strength.
Maltese: Il-kumpanija li tqiegħed Tresiba fis-suq sejra tipprovdi materjali edukattivi lill-professjonisti tal-kura tas-saħħa li huma mistennija li jagħtu kura jew jagħtu mediċini lill-pazjenti bid-dijabete, b'mod partikolari bil-għan li titqajjem sensibilizzazzjoni lejn il-formulazzjoni b'qawwa ogħla ta' Tresiba biex jiġi żgurat li l-pazjent ikollu l-preskrizzjoni tal-qawwa korretta.
English: Patients were also given rapid-acting insulin at mealtimes.
Maltese: Il-pazjenti ngħataw ukoll insulina li taġixxi malajr waqt l-ikel.
English: How has Tresiba been studied?
Maltese: Kif ġie studjat Tresiba?
English: What is the risk associated with Tresiba?
Maltese: X'inhu r-riskju assoċjat ma' Tresiba?
English: For the full list of side effects and restrictions with Tresiba, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji u r-restrizzjonijiet bi Tresiba, ara l-fuljett ta' tagħrif.
English: In children, the effects of Tresiba on blood glucose control were similar to those of insulin detemir.
Maltese: Fit-tfal, l-effetti ta' Tresiba fuq il-kontroll tal-glukożju fid-demm kienu simili għal dak tal-insulina detemir.